Pragmatic Approaches to Drug Safety Across the Premarketing and Postmarketing Continuum

This session will cover the Development Safety Update Report (DSUR) required in the EU and include a description of the modifications required for DSUR submission to FDA in lieu of the IND Annual Report. Abstracts of three sequential DSURs for a mock product progressing through development phases 1, 2, and 3 will be reviewed